Back to discover
Drug

Paltusotine hydrochloride

Approved · EMA

Also known as Palsonify, paltusotine (as hydrochloride), paltusotine HCl.

RxNorm2724364
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Approval: Palsonify (EMA)

Regulatory2026-04-23EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Paltusotine hydrochloride
Aliases & brands
Palsonifypaltusotine (as hydrochloride)paltusotine HCl
RxNorm CUI
2724364
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2026-04-23
Latest approval
2026-04-23
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2026-04-23Approval
Approval: Palsonify (EMA)

Indication: Palsonify is indicated for the medical treatment of adult patients with acromegaly.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Regulatory event sources are credited in the Regulatory Timeline above.